Systemic Corticosteroids in Hospitalized Patients with COVID-19: A Systematic Review of Randomized Controlled Trials

Authors

  • Cynthia Agustini Universitas Negeri Padang Author
  • Rizka Edya Universitas Prima Nusantara Bukittinggi Author

DOI:

https://doi.org/10.35730/7rqyf761

Keywords:

COVID-19, corticosteroids, dexamethasone, respiratory failure

Abstract

Background: Severe COVID-19 involves a dysregulated inflammatory response, and systemic corticosteroids were evaluated early in the pandemic. Randomized controlled trials (RCTs) have reported different results depending on the trial design and patient population. This systematic review summarizes their efficacy and safety.

Methods: RCTs of systemic corticosteroids in hospitalized adults with COVID-19, reporting mortality or organ-support outcomes, were eligible. Data were extracted and synthesized without meta-analysis following the SWiM reporting guideline, with qualitative risk-of-bias appraisal using RoB 2 domains.

Findings: Three RCTs (RECOVERY, CoDEX, REMAP-CAP) were included. In RECOVERY (6,425 patients), 28-day mortality was 22.9% with dexamethasone versus 25.7% with usual care (RR 0.83, 95% CI 0.75–0.93), with benefit in ventilated patients (RR 0.64, 95% CI 0.51–0.81) and in patients receiving oxygen (RR 0.82, 95% CI 0.72–0.94), but not in patients without respiratory support (RR 1.19, 95% CI 0.92–1.55). CoDEX (299 patients) reported more ventilator-free days (6.6 vs 4.0), and REMAP-CAP (403 patients) was stopped early without a clear difference in organ support-free days.

Conclusion: Dexamethasone reduced 28-day mortality in patients receiving oxygen or ventilation, and benefit was not shown in patients without respiratory support. The two smaller trials were underpowered for mortality

Downloads

Published

2026-09-30